Study for treatment of lymphatic filariosis in Science Translational Medicine published

March 15, 2019

Prof. Dr. Achim Hörauf, Director of Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn © Foto: Johann Saba/UK Bonn

PD Dr. Marc P. Hübner from the Institute of Medical Microbiology, Immunology and Parasitology © Foto: Katharina Wislsperger/UK Bonn

 

Neglected tropical diseases such as Lymphatic filariosis are common in tropical and subtropical areas. Here mostly poor people are affected.
An international consortium with a contribution of scientists from the Cluster of Excellence ImmunoSensation identified a new substance ABBV-4083 in the fight against adult worms, the cause of lymphatic filariosis.
Dr. Marc Hübner and Prof. Hörauf are working in the Institute of Medical Microbiology, Immunology and Parasitology at the University Hospital Bonn.

You can find the german press release here.

Publication: Mark J. Taylor, Thomas W. von Geldern, Louise Ford, Marc P. Hübner, Kennan Marsh, Kelly L. Johnston, Hanna T. Sjoberg, Sabine Specht, Nicolas Pionnier, Hayley E. Tyrer, Rachel H. Clare, Darren A. N. Cook, Emma Murphy, Andrew Steven, John Archer, Dominique Bloemker, Franziska Lenz, Marianne Koschel, Alexandra Ehrens, Haelly M. Metuge, Valerinne C. Chunda, Patrick W. Ndongmo Chounna, Abdel J. Njouendou, Fanny F. Fombad, Robert Carr, Howard E. Morton, Ghaith Aljayyoussi, Achim Hoerauf, Samuel Wanji, Dale J. Kempf, Joseph D. Turner, Stephen A. Ward: Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis, Science Translational Medicine, DOI: 10.1126/scitranslmed.aau2086